Table 3. MFS according to EMT markers combined with HPV status.
| Combination | MFS univariate analysis HR (95% CI)a | MFS multivariate analysis HR (95% CI)b |
|---|---|---|
|
EMTc
and HPV | ||
| Without or mild EMT—HPV neg | 1 | 1 |
| Without or mild EMT—HPV pos | 1.31 (0.46; 3.73) | 3.10 (0.90; 10.65) |
| Overt EMT—HPV negative | 3.21 (1.19; 8.62) | 3.15 (1.08; 9.20) |
| Overt EMT—HPV positive | 2.56 (0.53; 12.36) | 4.07 (0.64; 25.89) |
|
E-cadherin and HPV | ||
| E-cadherin (12–16)—HPV neg | 1 | 1 |
| E-cadherin (12–16)—HPV pos | 0.97 (0.36; 2.59) | 2.05 (0.69; 6.14) |
| E-cadherin (0–12)—HPV neg | 3.15 (0.93; 10.66) | 6.99 (1.49; 32.81) |
| E-cadherin (0–12)—HPV pos | 5.49 (1.07; 28.09) | 13.61 (1.46; 126.7) |
Abbreviations: CI=confidence interval; EMT=epithelial to mesenchymal transition; HPV=human papillomavirus; HR=hazard ratio; MFS=metastasis-free survival; UICC=union for international cancer control.
a
Univariate HR, stratified on hospital.
b
Multivariate HR, stratified on hospital and adjusted on age, gender, performance status, UICC stage, primary tumour sites, smoking status, alcohol consumption and primary treatment.
c
EMT according to vimentin expression—none: 0–10%, mild: 11–25%, overt: >25%.